Company intelligence / Profile preview

Brixton Biosciences

Cambridge, Massachusetts, United Statesbrixtonbio.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Brixton Biosciences has completed a first-in-human study of its Neural Ice™ injectable nerve block for knee osteoarthritis, achieving a 94% response rate in 16 patients. The company is now initiating pivotal randomized controlled trials for both chronic osteoarthritis knee pain and acute post-surgical knee replacement pain. The technology aims to provide non-addictive, drug-free, long-lasting local nerve blocks lasting several months from a single injection.

Therapeutic areas: RheumatologyNeurology
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Neural Ice

Phase 2

Indications: Osteoarthritis pain, Post-operative pain

Partnerships

None publicly disclosed; academic origin at Massachusetts General Brigham/Massachusetts General Hospital

Beyond the preview

Go deeper on Brixton Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Brixton Biosciences.